 | • レポートコード：MRC2Q12-19114 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、HIV治療薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 HIV治療薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 HIV治療薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 HIV治療薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのHIV治療薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のHIV治療薬の売上および2028年までの予測に焦点を当てています。 HIV治療薬のグローバル主要企業には、Gilead Sciences、Biocon Limited、Flamingo Pharmaceuticals Limited、IPCA Laboratories、Medisist Pharma、Affine Formulations Limitedなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 HIV治療薬市場は、タイプとアプリケーションによって区分されます。世界のHIV治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 2医薬品/ピル、3医薬品/ピル、4医薬品/ピル 【アプリケーション別セグメント】 男性用、女性用 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - HIV治療薬製品概要 - タイプ別市場（2医薬品/ピル、3医薬品/ピル、4医薬品/ピル） - アプリケーション別市場（男性用、女性用） - 調査の目的 ・エグゼクティブサマリー - 世界のHIV治療薬販売量予測2017-2028 - 世界のHIV治療薬売上予測2017-2028 - HIV治療薬の地域別販売量 - HIV治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別HIV治療薬販売量 - 主要メーカー別HIV治療薬売上 - 主要メーカー別HIV治療薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（2医薬品/ピル、3医薬品/ピル、4医薬品/ピル） - HIV治療薬のタイプ別販売量 - HIV治療薬のタイプ別売上 - HIV治療薬のタイプ別価格 ・アプリケーション別市場規模（男性用、女性用） - HIV治療薬のアプリケーション別販売量 - HIV治療薬のアプリケーション別売上 - HIV治療薬のアプリケーション別価格 ・北米市場 - 北米のHIV治療薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのHIV治療薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のHIV治療薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のHIV治療薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのHIV治療薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Gilead Sciences、Biocon Limited、Flamingo Pharmaceuticals Limited、IPCA Laboratories、Medisist Pharma、Affine Formulations Limited ・産業チェーン及び販売チャネル分析 - HIV治療薬の産業チェーン分析 - HIV治療薬の原材料 - HIV治療薬の生産プロセス - HIV治療薬の販売及びマーケティング - HIV治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - HIV治療薬の産業動向 - HIV治療薬のマーケットドライバー - HIV治療薬の課題 - HIV治療薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for HIV Medicines is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for HIV Medicines is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for HIV Medicines is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of HIV Medicines include Gilead Sciences, Biocon Limited, Flamingo Pharmaceuticals Limited, IPCA Laboratories, Medisist Pharma and Affine Formulations Limited, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the HIV Medicines manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional HIV Medicines market. Further, it explains the major drivers and regional dynamics of the global HIV Medicines market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Gilead Sciences
Biocon Limited
Flamingo Pharmaceuticals Limited
IPCA Laboratories
Medisist Pharma
Affine Formulations Limited
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
HIV Medicines Segment by Type
2 Medicines/Pill
3 Medicines/Pill
4 Medicines/Pill
HIV Medicines Segment by Application
Male
Female
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the HIV Medicines market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for HIV Medicines, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of HIV Medicines, also provides the sales of main regions and countries. Highlights of the upcoming market potential for HIV Medicines, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the HIV Medicines sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global HIV Medicines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for HIV Medicines sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Gilead Sciences, Biocon Limited, Flamingo Pharmaceuticals Limited, IPCA Laboratories, Medisist Pharma and Affine Formulations Limited, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of HIV Medicines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of HIV Medicines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV Medicines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 HIV Medicines Product Introduction
1.2 Market by Type
1.2.1 Global HIV Medicines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 2 Medicines/Pill
1.2.3 3 Medicines/Pill
1.2.4 4 Medicines/Pill
1.3 Market by Application
1.3.1 Global HIV Medicines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Male
1.3.3 Female
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global HIV Medicines Sales Estimates and Forecasts 2017-2028
2.2 Global HIV Medicines Revenue Estimates and Forecasts 2017-2028
2.3 Global HIV Medicines Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global HIV Medicines Sales by Region
2.4.1 Global HIV Medicines Sales by Region (2017-2022)
2.4.2 Global Sales HIV Medicines by Region (2023-2028)
2.5 Global HIV Medicines Revenue by Region
2.5.1 Global HIV Medicines Revenue by Region (2017-2022)
2.5.2 Global HIV Medicines Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global HIV Medicines Sales by Manufacturers
3.1.1 Global Top HIV Medicines Manufacturers by Sales (2017-2022)
3.1.2 Global HIV Medicines Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of HIV Medicines in 2021
3.2 Global HIV Medicines Revenue by Manufacturers
3.2.1 Global HIV Medicines Revenue by Manufacturers (2017-2022)
3.2.2 Global HIV Medicines Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by HIV Medicines Revenue in 2021
3.3 Global HIV Medicines Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global HIV Medicines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global HIV Medicines Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global HIV Medicines Sales by Type
4.1.1 Global HIV Medicines Historical Sales by Type (2017-2022)
4.1.2 Global HIV Medicines Forecasted Sales by Type (2023-2028)
4.1.3 Global HIV Medicines Sales Market Share by Type (2017-2028)
4.2 Global HIV Medicines Revenue by Type
4.2.1 Global HIV Medicines Historical Revenue by Type (2017-2022)
4.2.2 Global HIV Medicines Forecasted Revenue by Type (2023-2028)
4.2.3 Global HIV Medicines Revenue Market Share by Type (2017-2028)
4.3 Global HIV Medicines Price by Type
4.3.1 Global HIV Medicines Price by Type (2017-2022)
4.3.2 Global HIV Medicines Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global HIV Medicines Sales by Application
5.1.1 Global HIV Medicines Historical Sales by Application (2017-2022)
5.1.2 Global HIV Medicines Forecasted Sales by Application (2023-2028)
5.1.3 Global HIV Medicines Sales Market Share by Application (2017-2028)
5.2 Global HIV Medicines Revenue by Application
5.2.1 Global HIV Medicines Historical Revenue by Application (2017-2022)
5.2.2 Global HIV Medicines Forecasted Revenue by Application (2023-2028)
5.2.3 Global HIV Medicines Revenue Market Share by Application (2017-2028)
5.3 Global HIV Medicines Price by Application
5.3.1 Global HIV Medicines Price by Application (2017-2022)
5.3.2 Global HIV Medicines Price Forecast by Application (2023-2028)
6 North America
6.1 North America HIV Medicines Market Size by Type
6.1.1 North America HIV Medicines Sales by Type (2017-2028)
6.1.2 North America HIV Medicines Revenue by Type (2017-2028)
6.2 North America HIV Medicines Market Size by Application
6.2.1 North America HIV Medicines Sales by Application (2017-2028)
6.2.2 North America HIV Medicines Revenue by Application (2017-2028)
6.3 North America HIV Medicines Market Size by Country
6.3.1 North America HIV Medicines Sales by Country (2017-2028)
6.3.2 North America HIV Medicines Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe HIV Medicines Market Size by Type
7.1.1 Europe HIV Medicines Sales by Type (2017-2028)
7.1.2 Europe HIV Medicines Revenue by Type (2017-2028)
7.2 Europe HIV Medicines Market Size by Application
7.2.1 Europe HIV Medicines Sales by Application (2017-2028)
7.2.2 Europe HIV Medicines Revenue by Application (2017-2028)
7.3 Europe HIV Medicines Market Size by Country
7.3.1 Europe HIV Medicines Sales by Country (2017-2028)
7.3.2 Europe HIV Medicines Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific HIV Medicines Market Size by Type
8.1.1 Asia Pacific HIV Medicines Sales by Type (2017-2028)
8.1.2 Asia Pacific HIV Medicines Revenue by Type (2017-2028)
8.2 Asia Pacific HIV Medicines Market Size by Application
8.2.1 Asia Pacific HIV Medicines Sales by Application (2017-2028)
8.2.2 Asia Pacific HIV Medicines Revenue by Application (2017-2028)
8.3 Asia Pacific HIV Medicines Market Size by Region
8.3.1 Asia Pacific HIV Medicines Sales by Region (2017-2028)
8.3.2 Asia Pacific HIV Medicines Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America HIV Medicines Market Size by Type
9.1.1 Latin America HIV Medicines Sales by Type (2017-2028)
9.1.2 Latin America HIV Medicines Revenue by Type (2017-2028)
9.2 Latin America HIV Medicines Market Size by Application
9.2.1 Latin America HIV Medicines Sales by Application (2017-2028)
9.2.2 Latin America HIV Medicines Revenue by Application (2017-2028)
9.3 Latin America HIV Medicines Market Size by Country
9.3.1 Latin America HIV Medicines Sales by Country (2017-2028)
9.3.2 Latin America HIV Medicines Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa HIV Medicines Market Size by Type
10.1.1 Middle East and Africa HIV Medicines Sales by Type (2017-2028)
10.1.2 Middle East and Africa HIV Medicines Revenue by Type (2017-2028)
10.2 Middle East and Africa HIV Medicines Market Size by Application
10.2.1 Middle East and Africa HIV Medicines Sales by Application (2017-2028)
10.2.2 Middle East and Africa HIV Medicines Revenue by Application (2017-2028)
10.3 Middle East and Africa HIV Medicines Market Size by Country
10.3.1 Middle East and Africa HIV Medicines Sales by Country (2017-2028)
10.3.2 Middle East and Africa HIV Medicines Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Corporation Information
11.1.2 Gilead Sciences Overview
11.1.3 Gilead Sciences HIV Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Gilead Sciences HIV Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Gilead Sciences Recent Developments
11.2 Biocon Limited
11.2.1 Biocon Limited Corporation Information
11.2.2 Biocon Limited Overview
11.2.3 Biocon Limited HIV Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Biocon Limited HIV Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Biocon Limited Recent Developments
11.3 Flamingo Pharmaceuticals Limited
11.3.1 Flamingo Pharmaceuticals Limited Corporation Information
11.3.2 Flamingo Pharmaceuticals Limited Overview
11.3.3 Flamingo Pharmaceuticals Limited HIV Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Flamingo Pharmaceuticals Limited HIV Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Flamingo Pharmaceuticals Limited Recent Developments
11.4 IPCA Laboratories
11.4.1 IPCA Laboratories Corporation Information
11.4.2 IPCA Laboratories Overview
11.4.3 IPCA Laboratories HIV Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 IPCA Laboratories HIV Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 IPCA Laboratories Recent Developments
11.5 Medisist Pharma
11.5.1 Medisist Pharma Corporation Information
11.5.2 Medisist Pharma Overview
11.5.3 Medisist Pharma HIV Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Medisist Pharma HIV Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Medisist Pharma Recent Developments
11.6 Affine Formulations Limited
11.6.1 Affine Formulations Limited Corporation Information
11.6.2 Affine Formulations Limited Overview
11.6.3 Affine Formulations Limited HIV Medicines Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Affine Formulations Limited HIV Medicines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Affine Formulations Limited Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 HIV Medicines Industry Chain Analysis
12.2 HIV Medicines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 HIV Medicines Production Mode & Process
12.4 HIV Medicines Sales and Marketing
12.4.1 HIV Medicines Sales Channels
12.4.2 HIV Medicines Distributors
12.5 HIV Medicines Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 HIV Medicines Industry Trends
13.2 HIV Medicines Market Drivers
13.3 HIV Medicines Market Challenges
13.4 HIV Medicines Market Restraints
14 Key Findings in The Global HIV Medicines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer